Gastrointestinal Hormones

HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.
DrugDrug NameDrug Indication
DB00040GlucagonFor treatment of severe hypoglycemia, also used in gastrointestinal imaging
DB00183PentagastrinUsed as a diagnostic aid for evaluation of gastric acid secretory function
DB04914G17DTIntended for the treatment of various forms of cancer.
DB06260AviptadilNot Available
DB06655LiraglutideLiraglutide is indicated in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus[Label]. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease[Label].
DB08862CholecystokininFor use as a diagnostic aid for evaluation of gallbladder disorders. It is also used in conjunction with secretin in pancreatic insufficiency [L1634].
DB08900TeduglutideTreatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
DB09043AlbiglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09045DulaglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09142SincalideAs the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.
DB09527Secretin porcineNot Available
DB13928SemaglutideSemaglutide is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct of diet and exercise. The approved therapeutic doses are 0.5 mg and 1 mg.[L1068] Diabetes mellitus type 2 is a long-term metabolic disorder characterized by high blood sugar, insulin resistance and lack of insulin. Its onset is determined by the loss ability of beta cells to respond to an increased plasma glucose. This disease is predominantly caused by lifestyle factors like overweight and obesity. The key feature on type 2 diabetes is the presence of insulin resistance which reduced the capacity of insulin to exert its functions at normal at any given concentration. The secretion of insulin is stimulated by the action of incretins in the gut like glucagon-like peptide 1, which also delays gastric emptying and induces satiety, and glucose-dependent insulinotropic polypeptide.[T59]
DB14027TaspoglutideNot Available
DB14145NepiderminNot Available
DB09532Secretin humanIndicated for the stimulation of: - pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction [FDA Label]. - gastrin secretion to aid in the diagnosis of gastrinoma [FDA Label]. - pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) [FDA Label].
DB05004Peptide YY (3-36)Investigated for use/treatment in metabolic disease and obesity.
DB15217Gastric inhibitory polypeptideNot Available
DrugDrug NameTargetType
DB00040GlucagonGlucagon receptortarget
DB00040GlucagonGlucagon-like peptide 2 receptortarget
DB00040GlucagonGlucagon-like peptide 1 receptortarget
DB00183PentagastrinGastrin/cholecystokinin type B receptortarget
DB00183PentagastrinCholinesteraseenzyme
DB06655LiraglutideGlucagon-like peptide 1 receptortarget
DB06655LiraglutideDipeptidyl peptidase 4enzyme
DB06655LiraglutideNeprilysinenzyme
DB06655LiraglutideSerum albumincarrier
DB08862CholecystokininSolute carrier organic anion transporter family member 1B3transporter
DB08862CholecystokininCholecystokinin receptor type Atarget
DB08862CholecystokininRAF proto-oncogene serine/threonine-protein kinasetarget
DB08862CholecystokininMitogen-activated protein kinase 3target
DB08862CholecystokininPro-epidermal growth factortarget
DB08862CholecystokininProtein kinase C beta typetarget
DB08862CholecystokininGastrin/cholecystokinin type B receptortarget
DB08862CholecystokininSolute carrier organic anion transporter family member 1B1transporter
DB08862CholecystokininSolute carrier organic anion transporter family member 2B1transporter
DB08900TeduglutideGlucagon-like peptide 2 receptortarget
DB09043AlbiglutideGlucagon-like peptide 1 receptortarget
DB09045DulaglutideGlucagon-like peptide 1 receptortarget
DB09142SincalideSolute carrier organic anion transporter family member 1B3transporter
DB13928SemaglutideSerum albumincarrier
DB13928SemaglutideDipeptidyl peptidase 4enzyme
DB13928SemaglutideNeprilysinenzyme
DB13928SemaglutideGlucagon-like peptide 1 receptortarget
DB13928SemaglutideSolute carrier organic anion transporter family member 1B1transporter
DB13928SemaglutideSolute carrier organic anion transporter family member 1B3transporter
DB13928SemaglutideLipoprotein lipaseenzyme
DB13928SemaglutideAlpha-amylase 1enzyme
DB09532Secretin humanSecretin receptortarget
DB05004Peptide YY (3-36)Neuropeptide Y receptor type 2target
DB05004Peptide YY (3-36)Neuropeptide Y receptor type 1target
DB05004Peptide YY (3-36)Neuropeptide Y receptor type 5target
DB05004Peptide YY (3-36)Neuropeptide Y receptor type 4target